Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1999 • 1,263 citations

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

1994 • 958 citations

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

1998 • 820 citations

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

1994 • 749 citations

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

1996 • 584 citations

Biochemistry and molecular biology of the human CYP2C subfamily

1994 • 534 citations

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1997 • 309 citations

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

1991 • 273 citations

The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase

1997 • 269 citations

Identification and Functional Characterization of a New CYP2C9 Variant (CYP2C9*5) Expressed among African Americans

2001 • 253 citations

Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone

1999 • 230 citations

Variable contribution of cytochromes p450 2d6, 2c9 and 3a4 to the 4-hydroxylation of tamoxifen by human liver microsomes

1997 • 221 citations

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

1998 • 203 citations

Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily

1991 • 200 citations

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.

1995 • 199 citations

The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics

1998 • 178 citations

Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.

1997 • 178 citations

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

1999 • 169 citations

N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes.

1995 • 157 citations

Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.

2000 • 151 citations

The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.

1990 • 144 citations

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.

1999 • 144 citations

Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus

2000 • 130 citations

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.

1998 • 129 citations

Genetic Polymorphism of the CYP2C Subfamily and Excessive Serum Phenytoin Concentration With Central Nervous System Intoxication

2000 • 121 citations

[23] Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism

1996 • 115 citations

Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes.

1991 • 111 citations

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.

1999 • 109 citations

N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism

1996 • 81 citations

Cytochromes P450 mediating the N‐demethylation of amitriptyline

1997 • 72 citations

Catalytic Activity of Three Variants (Ile, Leu, and Thr) at Amino Acid Residue 359 in Human CYP2C9 Gene and Simultaneous Detection Using Single-Strand Conformation Polymorphism Analysis

2000 • 71 citations

The Effect of Different Sulfonamides on Phenytoin Metabolism in Man

1979 • 64 citations

Gene Structure and Upstream Regulatory Regions of Human CYP2C9 and CYP2C18

1993 • 62 citations

Extent of Urinary Excretion of p-Hydroxyphenytoin in Healthy Subjects Given Phenytoin

1985 • 56 citations

Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.

1994 • 45 citations

In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines

1999 • 35 citations

Fallacious Results from Measuring Salivary Carbamazepine Concentrations

1985 • 32 citations

Lung cancer risk in relation to mephenytoin hydroxylation activity

1997 • 12 citations

METABOLISM OF ANTICONVULSANT DRUGS

1981 • 7 citations

Plasma Salicylate Levels In Rheumatoid Arthritis: A Comparison Between Micro-Encapsulated And Conventional Aspirin

1979 • 6 citations